

# GENMAB A/S

ISIN: DK0010272202 WKN: - Asset Class: **Stock**

## Company

2024/04/26 16:59:56



Price

**1,954.50**

DKK

Difference

2.04% (39.00)



## Contact Details

GENMAB A/S

Tel: +45-70-20-27-28

--

Fax: +

Carl Jacobsens Vej 30, Valby  
2500 Copenhagen

Web: <http://www.genmab.com>

E-mail: [info@genmab.com](mailto:info@genmab.com)

## Company Profile

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	33,139,000,000		28,377,000,000		22,736,000,000	
<b>Common stock capital</b>		66,000,000		66,000,000		66,000,000
<b>Fixed assets</b>	2,150,000,000		1,901,000,000		1,891,000,000	
<b>Equity capital of a company</b>		31,610,000,000		27,441,000,000		22,196,000,000
<b>Cash and cash equivalents</b>	14,867,000,000		9,893,000,000		8,957,000,000	
<b>Accrued liabilities</b>		0		11,000,000		13,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		2,484,000,000		1,823,000,000		1,568,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		1,195,000,000		1,014,000,000		863,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		515,000,000		480,000,000		487,000,000
<b>Total assets</b>	35,289,000,000	35,289,000,000	30,278,000,000	30,278,000,000	24,627,000,000	24,627,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	2,204	1,660	1,212
<b>Equity ratio</b>	89.57%	90.63%	90.13%
<b>Debt-equity ratio</b>	11.64%	10.34%	10.95%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	22.80%	21.51%	24.48%

# GENMAB A/S

ISIN: DK0010272202 WKN: - Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	16,474,000,000	14,595,000,000	8,482,000,000
<b>Net income</b>	4,352,000,000	5,522,000,000	3,008,000,000
<b>EBIT</b>	633,622,500	902,761,200	509,445,900
<b>Operating income before taxes</b>	5,637,000,000	7,035,000,000	3,983,000,000
<b>Cash Flow</b>	7,380,000,000	3,912,000,000	2,228,000,000
<b>Net interest income</b>	912,000,000	303,000,000	184,000,000
<b>Research and development expenses</b>	7,435,000,000	5,346,000,000	4,004,000,000
<b>Income taxes</b>	1,285,000,000	1,513,000,000	975,000,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	1,002,343	1,179,030	938,479

## Board of Directors

Deirdre Connelly	Chairman of Supervisory Board
Anders Pedersen	Member of Supervisory Board
Mijke Zachariasse	Member of Supervisory Board
Paolo Augusto Paoletti	Member of Supervisory Board
Elizabeth O'Farrell	Member of Supervisory Board
Martin Schultz	Member of Supervisory Board
Pernille Erenbjerg	Member of Supervisory Board
Rolf K. Hoffmann	Member of Supervisory Board
Takahiro Hamatani	Member of Supervisory Board

## Members of Management Board

Jan G. J. van de Winkel	Chairman of Managing Board
Judith Klimovsky	Member of Executive Committee
Martine J. van Vugt	Member of Executive Committee
Anthony Mancini	Member of Executive Committee
Anthony Pagano	Member of Executive Committee
Birgitte Stephensen	Member of Executive Committee
Christopher Cozic	Member of Executive Committee
Tahamtan Ahmadi	Member of Executive Committee